S higella is an enteric bacterial pathogen that causes diarrhea (sometimes bloody), fever, and cramps (1). An estimated 500,000 Shigella infections occur annually in the United States (2). Shigella transmission is fecal-oral; it is easily spread person-to-person because of a low infectious dose. Outbreaks are most frequently documented in childcare settings but have also been reported among men who have sex with men (MSM) (3-7). Shigella infections are typically selflimiting, but treatment is recommended for patients with severe illness or underlying immunocompromising conditions (1,8). Antimicrobial drug treatment might shorten illness duration and is often used in childcare-associated outbreaks to prevent secondary transmission (1,8). When Shigella antimicrobial drug susceptibilities are unknown (e.g., when empiric therapy is started before culture and sensitivity results are available) or if the isolate is resistant to ampicillin and trimethoprim/sulfamethoxazole, oral treatment options include ciprofloxacin or azithromycin (1). However, fluoroquinolones, including ciprofloxacin, are generally avoided for treatment in children because of the risk for musculoskeletal damage (9). The emergence of Shigella with decreased susceptibility to azithromycin (DSA) has been reported in Asia, Europe, North America, and Oceania (10-17). Local outbreaks and intercontinental sexual transmission of DSA-Shigella have been observed among MSM (10,15,18-20). Co-infection with other enteric pathogens and sexually transmitted diseases (STDs) have also been reported among MSM (20-24). In 2016, the Clinical and Laboratory Standards Institute (CLSI) defined epidemiologic cutoff values for azithromycin resistance in S. sonnei or S. flexneri for the first time (25). Previously, the National Antimicrobial Resistance Monitoring System (NARMS) had documented DSA (azithromycin MIC >16 µg/ mL) among Shigella isolates; during 2011-2015, DSA prevalence increased from 0.9% to 6.1% among S. sonnei isolates and from 12.1% to 32.9% among S. flexneri